GlassScriptPhysician profile
Abdullah Shahid
NPI 1528400488
$1,336.76
in general payments reported to CMS, 2019-2025
16 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.02 · 2020: $47.75 · 2021: $127 · 2022: $277 · 2023: $98.34 · 2024: $228 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $465.70 | 2024-2025 | Impella |
| Recor Medical INC | $219.14 | 2025 | Paradise Ultrasound Renal Denervation System |
| Vifor Pharma, INC. | $180.90 | 2020-2022 | |
| Argenx US, INC. | $98.34 | 2023 | Vyvgart |
| Nevro Corp. | $86.02 | 2019 | |
| Aurinia Pharma U.S., INC. | $44.00 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $38.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.70 | 2022 | |
| Mallinckrodt Hospital Products INC. | $31.73 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $31.27 | 2022 | |
| Genzyme Corporation | $21.33 | 2022 | |
| Fresenius USA Marketing, INC. | $19.10 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.64 | 2022 | |
| Chiesi USA, INC. | $16.37 | 2024 | Cleviprex |
| Nxstage Medical, INC. | $15.26 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Shahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.